title: Positive-charged solid lipid nanoparticles as paclitaxel drug delivery  system in glioblastoma treatment.
abstract: Paclitaxel loaded solid lipid nanoparticles (SLN) of behenic acid were prepared with the coacervation technique. Generally, spherical shaped SLN with mean diameters in the range 300–600 nm were obtained. The introduction of charged molecules, such as stearylamine and glycol chitosan into the formulation allowed to obtain positive SLN with Zeta potential in the 8-20 mV range and encapsulation efficiency in the 25–90% range.Blood–brain barrier (BBB) permeability, tested in vitro through hCMEC/D3 cells monolayer, showed a significantly increase in the permeation of Coumarin-6, used as model drug, when vehicled in SLN. Positive-charged SLN do not seem to enhance permeation although stearylamine-positive SLN resulted the best permeable formulation after 24 h.Cytotoxicity studies on NO3 glioblastoma cell line demonstrated the maintenance of cytotoxic activity of all paclitaxel-loaded SLN that was always unmodified or greater compared with free drug. No difference in cytotoxicity was noted between neutral and charged SLN.Co-culture experiments with hCMEC/D3 and different glioblastoma cells evidenced that, when delivered in SLN, paclitaxel increased its cytotoxicity towards glioblastoma cells.
authors.forename: Daniela
authors.initials: D
authors.lastname: Chirio
authors.forename: Marina
authors.initials: M
authors.lastname: Gallarate
authors.forename: Elena
authors.initials: E
authors.lastname: Peira
authors.forename: Luigi
authors.initials: L
authors.lastname: Battaglia
authors.forename: Elisabetta
authors.initials: E
authors.lastname: Muntoni
authors.forename: Chiara
authors.initials: C
authors.lastname: Riganti
authors.forename: Elena
authors.initials: E
authors.lastname: Biasibetti
authors.forename: Maria Teresa
authors.initials: MT
authors.lastname: Capucchio
authors.forename: Alberto
authors.initials: A
authors.lastname: Valazza
authors.forename: Pierpaolo
authors.initials: P
authors.lastname: Panciani
authors.forename: Michele
authors.initials: M
authors.lastname: Lanotte
authors.forename: Laura
authors.initials: L
authors.lastname: Annovazzi
authors.forename: Valentina
authors.initials: V
authors.lastname: Caldera
authors.forename: Marta
authors.initials: M
authors.lastname: Mellai
authors.forename: Gaetano
authors.initials: G
authors.lastname: Filice
authors.forename: Silvia
authors.initials: S
authors.lastname: Corona
authors.forename: Davide
authors.initials: D
authors.lastname: Schiffer
mesh_terms: D000972:Antineoplastic Agents, Phytogenic / Q000008:administration & dosage* / Q000493:pharmacokinetics / Q000627:therapeutic use; D001812:Blood-Brain Barrier / Q000166:cytology / Q000187:drug effects / Q000378:metabolism*; D001932:Brain Neoplasms / Q000188:drug therapy / Q000473:pathology*; D045744:Cell Line, Tumor; D002463:Cell Membrane Permeability; D002470:Cell Survival / Q000187:drug effects; D004305:Dose-Response Relationship, Drug; D004337:Drug Carriers / Q000737:chemistry; D016503:Drug Delivery Systems; D065546:Drug Liberation; D004355:Drug Stability; D005909:Glioblastoma / Q000188:drug therapy / Q000473:pathology*; D006801:Humans; D008055:Lipids / Q000737:chemistry; D053758:Nanoparticles / Q000737:chemistry; D017239:Paclitaxel / Q000008:administration & dosage* / Q000493:pharmacokinetics / Q000627:therapeutic use; D010316:Particle Size; D013499:Surface Properties
chemical_list: D000972:Antineoplastic Agents, Phytogenic; D004337:Drug Carriers; D008055:Lipids; D017239:Paclitaxel